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Use routinely collected healthcare data to assess outcomes and risks for patients 
Data Sources
• Practitioner
• Hospital
• Laboratory
• Prescribing
• Genetic
Data Issues
• Biased
• Outcome coding
• Low outcomes rates 
• Treatments changes
Analysis approach
• Stratify patients into 
similar groups
• Group similar 
outcomes (ICD.10)
Advantages
• Balanced 
comparisons
• Leverage 
relationships
Choice of Method: Bayesian analysis
• Outcome occurrence rates
• Multiple outcomes
• Hierarchical models
• Sharing and shrinkage
• Scanning large numbers of 
outcomes
• Suitable for accumulating data
• Decision support
Results
• Posterior probabilities are used to 
assess the association of outcomes 
with treatments. e. g. 𝑃(𝜗𝑏𝑗,ℎ
𝑐 > 0)
• Obtain estimates of rates for 
different patient stratifications
• Identify interesting outcomes
• Adjusting for multiple comparison 
issues.
• Provided the initial assumptions 
are correct.
Case study: Direct oral anticoagulant (DOAC) Scotland study (2011 – 2015)1
Patient stratification
Outcome groupings (ICD.10)
Outcome Grouping Group description
Ischemic stroke I00-I99 Circulatory system
Haemorrhagic stroke I00-I99 Circulatory system
Systemic embolism I00-I99 Circulatory system
Pulmonary embolism I00-I99 Circulatory system
Myocardial infarction I00-I99 Circulatory system
Transient ischaemic attack G00-G99 Nervous system
Gastrointestinal bleed BLEED Bleeds
Other bleed BLEED Bleeds
Other ADR OTHERADR Adverse Drug Reaction
Results
Name Sex Age Concomitant
Medicines
M/0-64/0-4 M 0-64 0-4
M/0-64/5+ M 0-64 5+
M/65+/0-4 M 65+ 0-4
M/65+/5+ M 65+ 5+
F/0-64/0-4 F 0-64 0-4
F/0-64/5+ F 0-64 5+
F/65+/0-4 F 65+ 0-4
F/65+/5+ F 65+ 5+
Direct Oral Anticoagulants
*Rivaroxaban is the baseline treatment
Data
• Scottish Morbidity Records (SMR0/SMR1)
• Prescribing Information (PIS)
• National Records of Scotland (NRS)
Outcome Grouping Treatment Increase/Decrease
Myocardial Infarction Circulatory system Apixaban Increase
Other bleed Bleeds Apixaban Decrease
Other bleed Bleeds Dabigatran Decrease
Pulmonary embolism Circulatory system Dabigatran Decrease
Outcomes with increased/decreased rate compared to Rivaroxaban
Summary
The existence of large scale data sources containing the health records of thousands of patients provides an opportunity and a requirement to move beyond a single variable analysis to develop methods capable of analysing multiple outcomes, providing the possibility of moving towards a more precise approach to medicine 
delivery. Hierarchical Bayesian methods are a suitable approach for analysing this type of data. Hierarchies of outcomes may be easily incorporated in models and posterior probabilities provide a method for assessing outcome occurrence. Bayesian methods are also well suited to handling the analysis of constantly 
accumulating data, such as healthcare records. 
1Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. British Journal of Clinical Pharmacology 2019; 85(2): 422–431. doi:10.1111/bcp.13814
